Bioteque (4107) Q2 2026 earnings summary

Executive summary

• Revenue for the six months ended June 30, 2026 was NT$1,134.6 million, up 8% year-over-year from NT$1,049.0 million.

• Net income for the six months ended June 30, 2026 was NT$297.3 million, a 20% increase from NT$247.0 million in the prior year period.

• Gross margin improved to 45% from 43% year-over-year.

• Earnings per share for the six months were NT$4.29 basic and NT$4.27 diluted, compared to NT$3.56 and NT$3.55, respectively, in the prior year.

Financial highlights

• Operating income for the six months ended June 30, 2026 was NT$372.2 million, up from NT$321.5 million year-over-year.

• Operating expenses increased to NT$142.4 million from NT$127.1 million year-over-year.

• Cash and cash equivalents at June 30, 2026 were NT$1,032.8 million, down from NT$1,244.4 million at June 30, 2025.

• Total assets at June 30, 2026 were NT$4,881.0 million, up from NT$4,747.8 million at June 30, 2025.

• Dividends of NT$5.50 per share (NT$381.1 million total) were distributed in 2026.

Outlook and guidance

• Management expects adoption of new IFRS standards in 2027 and 2028 to have no significant impact.

• No material changes in capital management or segment structure anticipated.